Does use of biosimilar G-CSF change plerixafor utilization during stem cell mobilization for autologous stem cell transplant?

Bone Marrow Transplant. 2020 Aug;55(8):1655-1657. doi: 10.1038/s41409-019-0744-5. Epub 2019 Nov 18.

Authors

Nadine Abdallah¹, Seongho Kim², Lois Ayash², Scott Klimecki³, Marie Ventimiglia³, Asif Alavi², Voravit Ratanatharathorn², Joseph Uberti², Abhinav Deol⁴

Affiliations

¹ Department of Medicine, Wayne State University/Detroit Medical Center, Detroit, MI, USA.
² Department of Oncology, Wayne State University/Karmanos Cancer Institute, Detroit, MI, USA.
³ Karmanos Cancer Institute, Detroit, MI, USA.
⁴ Department of Oncology, Wayne State University/Karmanos Cancer Institute, Detroit, MI, USA. deola@karmanos.org.

No abstract available

Publication types

Letter

MeSH terms

Benzylamines
Biosimilar Pharmaceuticals*
Cyclams
Granulocyte Colony-Stimulating Factor
Hematopoietic Stem Cell Mobilization
Heterocyclic Compounds*
Humans
Stem Cell Transplantation

Substances

Benzylamines
Biosimilar Pharmaceuticals
Cyclams
Heterocyclic Compounds
Granulocyte Colony-Stimulating Factor
plerixafor

Grants and funding

P30 CA022453/CA/NCI NIH HHS/United States